Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Lymphangioleiomyomatosis

Written2008-10Angelo M Taveira-DaSilva, Wendy K Steagall, Joel Moss
Translational Medicine Branch, NHLBI, NIH, Building 10, Room 6D05, MSC 1590, Bethesda, Maryland 20892-1590, USA

(Note : for Links provided by Atlas : click)

Identity

Atlas_Id 5135
Phylum Other:Lymphangioleiomyomatosis
Other namesLAM
Note Lymphangioleiomyomatosis (LAM) is a multi-system disease, affecting predominantly pre-menopausal women, that is characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to the formation of lung cysts, fluid-filled cystic tumors in the axial lymphatics (e.g., lymphangioleiomyomas), and abdominal tumors, primarily in the kidneys, comprising adipose cells, vascular structures and LAM cells (e.g., angiomyolipomas).

Clinics and Pathology

Disease Pulmonary disease
Note Pulmonary disease is the main cause of morbidity and mortality. LAM usually presents with progressive breathlessness or with spontaneous recurrent pneumothorax, chylous effusions (chylothorax and ascites), or hemorrhage within an angiomyolipoma. Computed tomography scans show numerous thin-walled cysts throughout the lungs (Figure 1A and 1B), renal angiomyolipomas (Figure 2), and lymphangioleiomyomas (Figure 3). Pulmonary function abnormalities include airflow obstruction and gas exchange abnormalities.
Lung lesions in LAM are characterized by nodular infiltrates and clusters of LAM cells near cystic lesions and along pulmonary blood vessels, lymphatics, and bronchioles (Figure 4A and 4B). Two types of LAM cells have been described: small spindle-shaped cells and larger, epithelioid-like cells with abundant cytoplasm. Both types of cells react with antibodies against smooth muscle cell-specific antigens (e.g., smooth muscle a-actin, vimentin, desmin) (Figure 5). The epithelioid LAM cells react with HMB-45, a monoclonal antibody that recognizes gp100, a premelanosomal protein (Figures 5, 6 and 7). The spindle-shaped cells are more likely to react with anti-proliferation cell nuclear antigen (PCNA) antibodies, suggesting a more proliferative state. Receptors for estrogen, progesterone, and growth factors have been identified in LAM cells. LAM cells appear to have neoplastic properties and may be capable of metastasis. In addition to their presence in lungs, lymphatics and kidneys, LAM cells have been isolated from blood, chyle, and urine.
Etiology The tumor suppressor genes TSC1 and TSC2 have been implicated in the etiology of LAM, as mutations and loss of heterozygosity in the TSC genes have been detected in LAM cells (Figure 7). TSC1 encodes hamartin, a protein that plays a role in the reorganization of the actin cytoskeleton, and TSC2 encodes tuberin, a protein with roles in cell growth and proliferation. TSC1 and TSC2 may function both individually and as a cytosolic complex.
Epidemiology LAM occurs in about one third of women with tuberous sclerosis complex (TSC), an autosomal dominant syndrome characterized by hamartoma-like tumor growths in various organs, cerebral calcifications, seizures, and mental retardation, that occurs in one of 5800 live births. Sporadic LAM is a relatively uncommon disease with a prevalence that has been estimated at 1-2.6/million women.
 
Figure 1. Chest CT scan of a patient with LAM (A) showing numerous thin-walled cysts distributed throughout the lungs. (B) The lung parenchyma is almost completely replaced by very small cysts.
Figure 2. Abdominal CT scan of a patient with LAM showing angiomyolipomas involving both kidneys.
Figure 3. Abdominal CT scan of a patient with LAM showing a large lymphangioleiomyoma located in the retroperitoneal area and surrounding the aorta and inferior vena cava.
Figure 4 A and B. LAM nodule comprising spindle-shaped cells and larger epithelioid cells (A). Nodules of various sizes (B) are seen in involved lung (hematoxylin-eosin; original magnification x50).
Figure 5. Immunohistochemistry of LAM cells. Immunoperoxidase method and counterstaining with hematoxylin. A and B: Immunoreactivity with a-smooth muscle actin antibodies. LAM cells show strong reactivity (A). Pulmonary vascular smooth muscle cells are also strongly positive (arrow). LAM cells in the walls of the lung cysts are also strongly reactive (arrow) (B) (original magnification x250 for each). C: Immunoreactivity with monoclonal antibody HMB-45. Immunoreactive cells are distributed in the periphery of LAM lung nodules (arrow) (original magnification x250). D: Immunoreactivity with monoclonal antibody HMB-45. Higher-magnification view of tissue shown in C. A strong granular reaction is present in large epithelioid LAM cells adjacent to epithelial cells covering LAM lung nodules (arrow) (D) (original magnification x1000).
 
Figure 6. Left panel: close-up of LAM nodule (hematoxylin-eosin). Right panel: same nodule showing positive immunocytochemistry stain for HMB 45 (original magnification x200).
Figure 7. Characteristics of LAM cells (A-C). Reaction of LAM cells cultured from lung and pulmonary artery smooth muscle cells (PASM) with monoclonal antibody against SMA (A). Reaction of cultured LAM cells and melanoma cells (MALME-3M) with monoclonal antibody HMB-45 (B). Fluorescence in situ hybridization (FISH) for TSC1 (green) and TSC2 (red) in LAM cells showing normal presence of two of each alleles as well as abnormal presence of TSC2 alleles (left) (C). FISH for TSC1 (green, arrow) and TSC2 (red, arrowhead) in LAM cell with one (right) or two TSC2 (left) alleles (C). Bar, 20 µm.
Treatment Because LAM is predominantly a disease of pre-menopausal women and may worsen during pregnancy, or following the administration of exogenous estrogens, hormonal manipulations have been employed. However, no controlled studies have been undertaken to determine their efficacy. A retrospective study of 275 patients found no difference in disease progression between patients treated with progesterone and patients who received no progesterone. There is also no evidence that suppression of ovarian function, either by oophorectomy or use of gonadotrophin-releasing hormone analogs, benefit patients with LAM.
Progress about the mechanisms regulating cell proliferation and migration, and angiogenesis and lymphangiogenesis, have provided a foundation for the development of new therapies. The mammalian target of rapamycin (mTOR) appears to play a role in regulating the growth and multiplication of LAM cells (Figure 8). An inhibitor of mTOR, sirolimus (rapamycin), an antifungal macrolide antibiotic approved for immunosuppression after solid organ transplantation, has been studied as a possible treatment for LAM. In a rat model of TSC (Eker rat) with a functionally null germline mutation of tsc2, which spontaneously develops renal cell carcinomas, treatment with sirolimus resulted in a decrease in size of kidney tumors by both a reduction in the percentage of proliferating cells, and extensive tumor cell death. An open label study with sirolimus undertaken in twenty patients with angiomyolipomas showed a reduction in tumor size to 53.2+/-26.6 % of baseline at one year. An improvement in some lung function parameters was also observed. A clinical trial [MILES trial (Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial)], to examine the effect of rapamycin on pulmonary function, is underway.
Patients with severe LAM or those who show an accelerated rate of decline in lung function may be referred to a lung transplantation center.
Evolution LAM is a chronic disease, which may span decades. A retrospective analysis of 402 patients seen at NIH from 1995 to 2006 showed that 22 had died, eight of whom had undergone lung transplantation. The mortality in this large cohort was 5.5%. Of the surviving 380 patients, 38 (10%) had lung transplantation. A recent study reported a ten year survival greater than 90%.

Genes involved and Proteins

Gene Name TSC1
Note TSC1 and TSC2 are tumor suppressor genes. TSC1 (9q34) encodes the 130kDa protein hamartin, while TSC2 (16p13.3) encodes the 200kDa protein tuberin. Hamartin and tuberin may have individual functions, but they also interact to form a cytosolic complex. Loss of heterozygosity of TSC2 has been detected in LAM lesions from lung and kidney, and mutations in TSC2 occur more frequently than those in TSC1 in patients with sporadic LAM. Hamartin may play a role in the reorganization of the actin cytoskeleton, with a lack of hamartin leading to a loss of focal adhesions and detachment from substrate, resulting in cell rounding. Hamartin induces an increase in the levels of RhoGTP , an activator of ERM (ezrin-radixin-moesin) proteins, and binds to activated ERM proteins. ERM proteins bind both filamentous actin and integral membrane proteins, thereby bridging the plasma membrane and cortical actin filaments.
Tuberin has roles in pathways controlling cell growth and proliferation (Figure 8). It is a negative regulator of cell cycle progression, and loss of tuberin function shortens the G1 phase of the cell cycle. Tuberin binds p27KIP1, a cyclin-dependent kinase inhibitor, thereby preventing its degradation and leading to inhibition of the cell cycle. Upon mutation of tuberin, p27 becomes mislocalized in the cytoplasm, allowing the cell cycle to progress.
Tuberin also integrates signals from growth factors and energy stores through its interaction with mTOR (mammalian target of rapamycin) (Figure 8). Tuberin has Rheb GAP (Ras homolog enriched in brain GTPase-activating protein) activity, which converts Rheb-GTP to Rheb-GDP, thereby inactivating Rheb. Rheb controls mTOR, a serine/threonine kinase that phosphorylates at least two substrates: 4E-BP1, allowing cap-dependent translation, and S6K1, leading to translation of 5' TOP (terminal oligopyrimidine tract)-containing RNAs. Phosphorylation of tuberin by Akt, which is known to be activated by growth factors, leads to inhibition of tuberin and results in cell growth and proliferation. Phosphorylation of tuberin by AMPK (AMP-activated kinase) activates tuberin and further promotes inhibition of cell growth in states of energy deprivation.
Tuberin may also have roles in endocytosis through its interaction with rabaptin-5 and in transcriptional activation through interaction with members of the retinoid X receptor (RXR) family.
Figure 8. Schematic model of TSC1 and TSC2 pathways. The TSC1/TSC2 complex has roles in cell cycle progression and in cell growth and proliferation. Tuberin binds p27KIP1, a cyclin-dependent kinase inhibitor, stabilizing it and resulting in inhibition of cell cycle progression. Tuberin also has Rheb GAP activity, which converts Rheb-GTP to Rheb-GDP, resulting in inactive Rheb. Rheb controls mTOR, which is a kinase that controls translation through the phosphorylation of 4E-BP1 and S6K1. Akt, when activated by growth factors, phosphorylates tuberin, leading to an inhibition of tuberin and resulting in cell growth and proliferation. However, when a state of low cellular energy exists, AMPK phosphorylates tuberin, activating it, and thereby inhibiting cell growth.

Bibliography

Pulmonary lymphangioleiomyomatosis and steroid receptors.
Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC.
Am J Clin Pathol. 1990 May;93(5):609-14.
PMID 2183584
 
Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis.
Bittmann I, Rolf B, Amann G, Lohrs U.
Hum Pathol. 2003 Jan;34(1):95-8.
PMID 12605373
 
Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.
Carsillo T, Astrinidis A, Henske EP.
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90.
PMID 10823953
 
Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
Castro AF, Rebhun JF, Clark GJ, Quilliam LA.
J Biol Chem. 2003 Aug 29;278(35):32493-6. Epub 2003 Jul 3.
PMID 12842888
 
Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis.
Chu SC, Horiba K, Usuki J, Avila NA, Chen CC, Travis WD, Ferrans VJ, Moss J.
Chest. 1999 Apr;115(4):1041-52.
PMID 10208206
 
High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.
Costello LC, Hartman TE, Ryu JH.
Mayo Clin Proc. 2000 Jun;75(6):591-4.
PMID 10852420
 
Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.
Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J.
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17462-7. Epub 2004 Dec 6.
PMID 15583138
 
Identification and characterization of the tuberous sclerosis gene on chromosome 16.
European Chromosome 16 Tuberous Sclerosis Consortium.
Cell. 1993 Dec 31;75(7):1305-15.
PMID 8269512
 
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.
Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX.
Am J Respir Crit Care Med. 2001 Aug 15;164(4):661-8.
PMID 11520734
 
TSC tumour suppressor proteins antagonize amino-acid-TOR signaling.
Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D.
Nat Cell Biol. 2002 Sep;4(9):699-704.
PMID 12172555
 
Lymphatic involvement in lymphangioleiomyomatosis.
Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J.
Ann N Y Acad Sci. 2008;1131:206-14. (Review).
PMID 18519973
 
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleimyomatosis (LAM).
Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA Jr, Krymskaya VP.
J Biol Chem. 2002 Aug 23;277(34):30958-67. Epub 2002 Jun 3.
PMID 12045200
 
Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.
Harari S, Cassandro R, Chiodini J, Taveira-DaSilva AM, Moss J.
Chest. 2008 Feb;133(2):448-54. Epub 2007 Dec 10.
PMID 18071009
 
Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members.
Henry KW, Yuan X, Koszewski NJ, Onda H, Kwiatkowski DJ, Noonan DJ.
J Biol Chem. 1998 Aug 7;273(32):20535-9.
PMID 9685410
 
Dysregulation of the TSC-mTOR pathway in human disease.
Inoki K, Corradetti MN, Guan KL.
Nat Genet. 2005 Jan;37(1):19-24.
PMID 15624019
 
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling.
Inoki K, Li Y, Zhu T, Wu J, Guan KL.
Nat Cell Biol. 2002 Sep;4(9):648-57.
PMID 12172553
 
TSC2 mediates cellular energy response to control cell growth and survival.
Inoki K, Zhu T, Guan KL.
Cell. 2003 Nov 26;115(5):577-90.
PMID 14651849
 
Lymphangioleiomyomatosis.
Johnson SR.
Eur Respir J. 2006 May;27(5):1056-65. (Review).
PMID 16707400
 
Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.
Karbowniczek M, Yu J, Henske EP.
Am J Pathol. 2003 Feb;162(2):491-500.
PMID 12547707
 
Tumour suppressors hamartin and tuberin: intracellular signaling.
Krymskaya VP.
Cell Signal. 2003 Aug;15(8):729-39.
PMID 12781866
 
The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.
Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A.
Nat Cell Biol. 2000 May;2(5):281-7.
PMID 10806479
 
TSC2: filling the GAP in the mTOR signaling pathway.
Li Y, Corradetti MN, Inoki K, Guan KL.
Trends Biochem Sci. 2004 Jan;29(1):32-8.
PMID 14729330
 
Identification of tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway.
Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC.
Mol Cell. 2002 Jul;10(1):151-62.
PMID 12150915
 
Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis gene TSC1 and TSC2.
Maruyama H, Ohbayashi C, Hino O, Tsutsumi M, Konishi Y.
Pathol Int. 2001 Aug;51(8):585-94.
PMID 11564212
 
Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.
Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J.
Am J Respir Cell Mol Biol. 1999 Sep;21(3):327-36.
PMID 10460750
 
Lymphangioleiomyomatosis. A clinical update.
McCormack FX.
Chest. 2008 Feb;133(2):507-16. (Review).
PMID 18252917
 
Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.
Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechle J, Brooks PG, Hedin CJ, Hunsberger S, Kristof AS.
Am J Respir Crit Care Med. 2001 Aug 15;164(4):669-71.
PMID 11520735
 
Characterization of the cytosolic tuberin-hamartin complex.
Nellist M, van Slegtenhorst MA, Goedbloed M, van den Ouweland AM, Halley DJ, van der Sluijs P.
J Biol Chem. 1999 Dec 10;274(50):35647-52.
PMID 10585443
 
TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J.
Cancer Res. 2007 Nov 1;67(21):10573-81.
PMID 17975002
 
Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.
Plank TL, Yeung RS, Henske EP.
Cancer Res. 1998 Nov 1;58(21):4766-70.
PMID 9809973
 
Proteins interacting with the tuberous sclerosis gene products.
Rosner M, Freilinger A, Hengstschlager M.
Amino Acids. 2004 Oct;27(2):119-28. Epub 2004 Sep 7.
PMID 15351877
 
The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.
Rosner M, Hanneder M, Siegel N, Valli A, Hengstschlger M.
Mutat Res. 2008 Mar-Apr;658(3):234-46. Epub 2008 Jan 12.
PMID 18291711
 
Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2.
Rosner M, Hengstschlager M.
J Biol Chem. 2004 Nov 19;279(47):48707-15. Epub 2004 Sep 8.
PMID 15355997
 
The NHLBI Lymphangioleiomyomatosis Registry : Characteristics of 230 Patients at Enrollment.
Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL; NHLBI LAM Registry Group.
Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11. Epub 2005 Oct 6.
PMID 16210669
 
Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP.
Am J Hum Genet. 1998 Apr;62(4):810-5.
PMID 9529362
 
Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase.
Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M.
J Biol Chem. 1997 Nov 14;272(46):29301-8.
PMID 9361010
 
Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.
Soucek T, Rosner M, Miloloza A, Kubista M, Cheadle JP, Sampson JR, Hengstschlager M.
Oncogene. 2001 Aug 9;20(35):4904-9.
PMID 11521203
 
Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.
Soucek T, Yeung RS, Hengstschlager M.
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15653-8.
PMID 9861025
 
Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis.
Steagall WK, Glasgow CG, Hathaway OM, Avila NA, Taveira-Dasilva AM, Rabel A, Stylianou MP, Lin JP, Chen X, Moss J.
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L800-8. Epub 2007 Jul 6.
PMID 17616646
 
The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangioleiomyomatosis.
Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP.
Am J Respir Crit Care Med. 2001 Jan;163(1):253-8.
PMID 11208653
 
Lymphangioleiomyomatosis.
Taveira-DaSilva AM, Steagall WK, Moss J.
Cancer Control. 2006 Oct;13(4):276-85. (Review)
PMID 17075565
 
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.
PMID 12271141
 
Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J.
Curr Biol. 2003 Aug 5;13(15):1259-68.
PMID 12906785
 
Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERMOP).
Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier JF.
Medicine (Baltimore). 1999 Sep;78(5):321-37.
PMID 10499073
 
Immunohistochemical analysis of proteins of Bcl-2 family in pulmonary Lymphangioleiomyomatosis : Association of Bcl-2 expression with hormonal receptor status.
Usuki J, Horiba K, Chu SC, Moss J, Ferrans VJ.
Arch Pathol Lab Med. 1998 Oct;122(10):895-902.
PMID 9786350
 
The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis.
Xiao G-H, Shoarinejad F, Jin F, Golemis EA, Yeung RS.
J Biol Chem. 1997 Mar 7;272(10):6097-100.
PMID 9045618
 
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D.
Nat Cell Biol. 2003 Jun;5(6):578-81.
PMID 12771962
 
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P.
Hum Mol Genet. 1998 Jun;7(6):1053-7.
PMID 9580671
 

Citation

This paper should be referenced as such :
Taveira-DaSilva, AM ; Steagall, WK ; Moss, J
Lymphangioleiomyomatosis
Atlas Genet Cytogenet Oncol Haematol. 2009;13(10):751-757.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Tumors/LymphangioLeiomyoID5135.html


Other genes implicated (Data extracted from papers in the Atlas) [ 3 ]

Genes FIGF MTOR TSC2
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Sep 10 13:34:56 CEST 2016


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.